Ligand Pharmaceuticals Inc. Stock OTC Bulletin Board
Stocks
US53220K1815
Pharmaceuticals
|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| 08-07 | RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating | MT |
| 08-06 | Ligand Pharmaceuticals Incorporated, Q2 2026 Earnings Call, Aug 06, 2026 |
| Market Cap | 5.76B 4.99B 4.67B 4.26B 8.02B 549B 8.15B 54.76B 21.45B 275B 21.61B 21.14B 917B | P/E 2026 * |
55.6x | P/E 2027 * | 33.7x |
|---|---|---|---|---|---|
| Enterprise Value | 5.76B 4.99B 4.67B 4.26B 8.02B 549B 8.15B 54.76B 21.45B 275B 21.61B 21.14B 917B | EV / Sales 2026 * |
19.8x | EV / Sales 2027 * | 15.1x |
| Free-Float |
97.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ligand Pharmaceuticals Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 66 | 05/12/2022 |
Melanie Herman
DFI | Director of Finance/CFO | 47 | 21/05/2015 |
Octavio Espinoza
DFI | Director of Finance/CFO | 56 | 01/11/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
John Kozarich
CHM | Chairman | 76 | 01/03/2003 |
Jason Aryeh
BRD | Director/Board Member | 57 | 27/09/2006 |
Todd Davis
BRD | Director/Board Member | 66 | 01/03/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.56% | +3.19% | +88.79% | +124.38% | 1,083B | |
| -0.39% | -0.00% | +49.08% | +48.51% | 626B | |
| -0.65% | +0.95% | +25.13% | +63.23% | 442B | |
| -1.30% | -0.47% | +47.32% | +37.06% | 363B | |
| -1.33% | -0.40% | +28.82% | +36.34% | 295B | |
| -0.91% | -2.79% | +5.54% | +5.28% | 248B | |
| +0.13% | +0.96% | +44.48% | +57.77% | 224B | |
| -2.72% | +1.41% | -6.88% | -51.81% | 210B | |
| +0.41% | +2.94% | +13.01% | +69.86% | 168B | |
| Average | -0.84% | +2.88% | +32.81% | +43.40% | 406.57B | |
| Weighted average by Cap. | -0.78% | +4.29% | +48.03% | +63.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 291M 252M 236M 215M 405M 27.76B 412M 2.77B 1.08B 13.9B 1.09B 1.07B 46.36B | 381M 330M 309M 282M 531M 36.35B 540M 3.63B 1.42B 18.19B 1.43B 1.4B 60.7B |
| Net income | 112M 96.84M 90.66M 82.72M 156M 10.66B 158M 1.06B 416M 5.33B 420M 410M 17.8B | 189M 164M 153M 140M 263M 18.01B 267M 1.8B 704M 9.01B 709M 693M 30.07B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
